Interpace Biosciences, Inc. (OTCMKTS:IDXG) Stock Short Interest Report for October

Interpace Biosciences, Inc. (OTCMKTS:IDXG) was the recipient of a large growth in short interest during the month of October. As of October 30th, there was short interest totaling 13 shares, a growth of 550.0% from the October 15th total of 2 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily volume of 4,223 shares, the days-to-cover ratio is currently 0.0 days.

Interpace Biosciences Stock Performance

OTCMKTS IDXG remained flat at $6.20 during trading hours on Friday. The company had a trading volume of 1,802 shares, compared to its average volume of 1,678. The company’s 50-day moving average is $6.53 and its two-hundred day moving average is $8.04. The stock has a market cap of $34.35 million, a PE ratio of 15.50 and a beta of 0.67. Interpace Biosciences has a 52-week low of $4.95 and a 52-week high of $7.45.

Interpace Biosciences (OTCMKTS:IDXG) last announced its quarterly earnings results on Monday, August 10th. The business services provider reported $0.05 earnings per share (EPS) for the quarter. Interpace Biosciences had a return on equity of 145.40% and a net margin of 67.64%. The company had revenue of $9.13 million during the quarter.

About Interpace Biosciences

Interpace Biosciences, Inc. is a molecular diagnostics company focused on improving the diagnosis and management of cancer and other complex diseases. The company develops and commercializes molecular tests that help physicians evaluate disease risk, guide treatment decisions and reduce uncertainty associated with conventional diagnostic procedures. Its portfolio has included tests for thyroid, pancreatic and gastroesophageal conditions. ThyGeNEXT and ThyraMIR are designed to help evaluate indeterminate thyroid nodules, while PancraGEN supports risk assessment for pancreatic cysts.